Drug Index


Mechanism :

Daclatasvir binds to the N-terminus within Domain 1 of HCV non-structural protein 5A (NS5A) and inhibits viral RNA replication and virion assembly.

Indication :

  • Treatment of chronic hepatitis C virus (HCV) genotype 1 or genotype 3 infection in combination with sofosbuvir, with or without ribavirin
  • Chronic hepatitis C (genotype 2); Chronic hepatitis C (genotype 4); Chronic hepatitis C (genotype 5 or 6)

Contraindications :

Hypersensitivity to daclatasvir or any component of the formulation; concurrent use with strong inducers of CYP3A4 and P-glycoprotein (P-gp).

Dosing :

<18 years:
Safety and efficacy not established.
Genotype 1, 3 and 4:
60 mg PO OD x 12 weeks. For genotype 2 can give for 16-24 weeks.

Adverse Effect :

Headache, Fatigue, Nausea, Diarrhea, Elevated lipase.

Interaction :

Amiodarone: Daclatasvir may enhance the bradycardic effect of Amiodarone.
CYP3A4 Inducers: May decrease the serum concentration of Daclatasvir.
CYP3A4 Inhibitors: May increase the serum concentration of Daclatasvir.
P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates.
Warfarin: Daclatasvir may enhance the anticoagulant effect of Warfarin.

Hepatic Dose :

No dosage adjustments are recommended.
12/20/2023 06:04:10 Daclatasvir
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0